Reduction of biological agent dose in rheumatic diseases: Descriptive analysis of 153 patients in clinical practice conditions;Reducción de dosis de terapias biológicas en enfermedades reumáticas: Análisis descriptivo de 153 pacientes en condiciones de práctica clínica

Reumatologia Clinica

Volumn 10, Issue 1, 2014, Pages 10-16

  Inciarte Mundo, José ^a   Hernández, M Victoria ^a   Rosario, Violeta ^a   Ruiz Esquide, Virginia ^a   Cabrera Villalba, Sonia ^a   Ramírez, Julio ^a   Cañete, Juan D ^a   Sanmartí, Raimon ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Artropat as cr nicas; Biological therapy; Chronic arthritis; Dose reduction; Reducci n de dosis; Terapia biol gica

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84895067247     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2013.04.012     Document Type: Article

References (35)

1. Furst D.E., Keystone E.C., Braun J., Breedveld F.C., Burmester G.R., de Benedetti F., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011. Ann Rheum Dis 2012, 71(Suppl 2):i2-i45.
2. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev 2009, CD007848. 10.1002/14651858.CD007848.pub2.
3. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, CD008794. 10.1002/14651858.CD008794.pub2.
4. Listing J., Strangfeld A., Rau R., Kekow J., Gromnica-Ihle E., Klopsch T., et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. Arthritis Res Ther 2006, 8:R66.
5. Baraliakos X., Braun J. Biologic therapies for spondyloarthritis: What is new?. Curr Rheumatol Rep 2012, 14:422-427.
6. Brocq O., Albert C., Millasseau E., Grisot C., Flory C., Roux C.H., et al. Effect of discontinuing TNFalpha agonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009, 76:350-355.
7. Baraliakos X., Listing J., Brandt J., Zink A., Alten R., Burmester G., et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005, 7:R439-R444.
8. Lee J., Noh J.W., Hwang J.W., Oh J.M., Kim H., Lee Y.S., et al. Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010, 29:1149-1154.
9. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
10. Den Broeder, van der Maas A., van den Bemt B.J. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 2011, 49:1801-1803.
11. Prevoo M.L.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B.A., van Riel P.L., et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
12. De Punder Y.M., Fransen J., Kievit W., Houtman P.M., Visser H., van de Laar M.A., et al. The prevalence of clinical remission in RA patients treated with anti-TNF: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012, 51:1610-1617.
13. Van den Broek M., Klarenbeek N.B., Dirven L., van Shaaedenburg D., Hulsmans H.M., Kerstens P.J., et al. Discontinuation and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of BeSt study. Ann Rheum Dis 2011, 70:1389-1394.
14. Van der Kooij S.M., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Güler-Yüksel M., Zwinderman A.H., Kerstens P.J., et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009, 68:914-921.
15. Tanaka Y., Takeuchi T., Mimori T., Saito K., Nawata M., Kameda H., et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010, 69:1286-1291.
16. Saleem B., Keen H., Goeb V., Parmar R., Nizam S., Hensor E.M., et al. Patients with RA in remission on TNF blockers: When and whom can TNF blocker therapy be stopped?. Ann Rheum Dis 2010, 69:1636-1642.
17. Gibson J., Harris H., McLaren S. Reduced dose and frecuency of Anti-TNF therapy in rheumatic diseases [EULAR 2012. Abstract OP0148]. Ann Rheum Dis 2012, 71(Suppl 3):103.
18. Botsios C., Furlan A., Ostuni P., Sfriso P., Todesco S., Punzi L. Effects of low dose etanercept in mantaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis [EULAR 2012. Abstract OP0012]. Ann Rheum Dis 2007, 66(Suppl II):54.
19. Compán-Navarro V., Moreira V., Ariza-Ariza R., Hernández-Cruz B., Vargas-Lebrón C., Navarro-Sanabria F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011, 30:993-996.
20. Lee S.H., Lee Y.A., Hong S.J., Yang H.I. Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 2008, 27:179-181.
21. López-Vives L., Estrada P.V., Martín-Esteve I., Aparicio M., Rodriguez-Moreno J., Juanola X. Dose reduction and/or withdrawal of anti-TNF treatment in psoriatic arthritis [EULAR 2012 Abstract OP0161]. Ann Rheum Dis 2012, 71(Supple3):133.
22. Cantini F., Niccoli L., Cassará E., Kaloudi O., Nannini C. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study. Biologics 2012, 6:201-206.
23. Tornero-Molina J., Sanmartí-Sala R., Rodríguez V., Martín E., Marenco J.L., Gónzalez I., et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin 2010, 6:23-36.
24. Férnandez J.L., Juanola X., Cañete J.D., Torre J.C., García R., Queiro R., et al. Documento SER de consenso sobre el uso de teapia biológicas en artritis psoriásica. Reumatol Clin 2011, 7:179-188.
25. Juanola X., Zarco P., Sanz J., Muñoz S., Mulero J., Linares L.F., et al. Documento SER de consenso sobre el uso de terapias biológicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psoriásica. Reumatol Clin 2011, 7:113-123.
26. Den Broeder A.A., Creemers M.C., van Gestel A.M., van Riel P.L. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF alpha. Rheumatology 2002, 41:638-642.
27. Pavelka K., Jarošová K., Suchý D., Senolt L., Chroust K., Dusek L., et al. Increasing the infliximab dose in rheumatoid arthritis patients: A randomised, doble-blind study failed to confirm its efficacy. Ann Rheum Dis 2009, 68:1285-1289.
28. Van den Bemt B.J., den Broeder A.A., Snijders G.F., Hekster Y.A., van Riel P.L., Benraad B., et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008, 67:1697-1701.
29. Smolen J.S., Freundlich B., Pavelka K., Nash P., Miranda P., Constance H., et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013, 10.1016/S0140-6736(12)61811-X.
30. Berthelot J.M., Varin S., Cormier G., Tortellier L., Guillot P., Glemarec J., et al. 25mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine 2007, 74:144-147.
31. Evaluation of a standardized protocol for dose reduction in patients with Spondylarthropathies and clinical remission with anti-TNF therapy. ClinicalTrials.gov Identifier: NCT01604629.
32. Tak P.P., Rigby W.F., Rubbert-Roth A., Peterfy C.G., van Vollenhoven R.F., Stohl W., et al. Inhibition of joint damage and improved clinical outcome with rituximab plus methotrexate in early rheumatoid arthritis: The IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
33. Chaztzidionysiou K., Lie E., Nasonov E.L., Lukina G., Hetland M.L., Ulrik T., et al. Efficacy of different doses of rituximab for the treatment of RA: data from the CERERRA collaboration [EULAR 2012 Abstract OP0028]. Ann Rheum Dis 2012, 71(Suppl 3):110.
34. Dougados M., Combe B., le Loët X., Tebib J., Sibilia J., Rouanet S., et al. One single infusion of rituximab 1g might be sufficient in the long-term management of rheumatoid arthritis patients responding to a first cycle of rituximab (2×1g): Results of a 2-year multicenter randomized controlled trial [EULAR 2012 Poster session THU0087]. Ann Rheum Dis 2012, 71(Suppl 3):121.
35. Kobelt G., Lekander I., Lang A., Raffeiner B., Botsios C., Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011, 27:193-200.